JAK2 and acute lymphoblastic leukemia: NGS was performed in 154 patients with Ph-like ALL (30 with CRLF2 and 124 with no CRLF2) and 160 patients with non-Ph-like ALL. The genetic alteration was identified in 91% of patients. CRLF2-20%, JAK2 and EPOR-18%, other JAK-STAT activating sequence mutation-20%, ABL class fusion-22%, RAS pathway mutation-10%, other kinase mutations-1% and no kinase mutation-9%.